RYTHMOIRESEARCH
SMS Research Updates ↗

AZN / Healthcare

ASTRAZENECA PLC

Pharmaceutical Preparations

Company overview

ASTRAZENECA PLC is an SEC-reporting issuer listed on NYSE under AZN. Its SEC industry description is Pharmaceutical Preparations. This profile organizes annual financial disclosures for research; sector labels are editorial groupings, not GICS classifications.

Drug developers, device manufacturers and care providers depend on distinct clinical, reimbursement and operating economics.

Business segments

Segment-level revenue is not included in this standardized dataset. Consult the business and segment notes in the linked annual filing for the issuer’s actual reporting segments.

Selected fundamentals

Annual reporting currency: USD. Financial amounts are in millions, except per-share figures and ratios.

Latest period 2025-12-31 · prior period 2024-12-31
Metric2025-12-312024-12-31Source filed
RevenueUSD 58,739mUSD 54,073m2026-02-24
Operating incomeUSD 13,743mUSD 10,003m2026-02-24
Net incomeUSD 10,233mUSD 7,041m2026-02-24
Diluted EPSUSD 6.54USD 4.502026-02-24
Operating cash flowUSD 14,575mUSD 11,861m2026-02-24
Capital expenditureNot availableNot available2026-02-24
Free cash flowNot availableNot available2026-02-24
Gross margin81.90%81.12%2026-02-24
Operating margin23.40%18.50%2026-02-24

FCF = operating cash flow − purchases of property, plant and equipment. Missing tags remain unavailable. Standardized cash-flow comparisons are particularly limited for financial businesses.

Inspect original metric provenance
{
  "revenue": {
    "start": "2025-01-01",
    "end": "2025-12-31",
    "val": 58739000000,
    "accn": "0001104659-26-019130",
    "fy": 2025,
    "fp": "FY",
    "form": "20-F",
    "filed": "2026-02-24",
    "frame": "CY2025",
    "tag": "ifrs-full:Revenue",
    "unit": "USD"
  },
  "netIncome": {
    "start": "2025-01-01",
    "end": "2025-12-31",
    "val": 10233000000,
    "accn": "0001104659-26-019130",
    "fy": 2025,
    "fp": "FY",
    "form": "20-F",
    "filed": "2026-02-24",
    "frame": "CY2025",
    "tag": "ifrs-full:ProfitLoss",
    "unit": "USD"
  },
  "grossProfit": {
    "start": "2025-01-01",
    "end": "2025-12-31",
    "val": 48106000000,
    "accn": "0001104659-26-019130",
    "fy": 2025,
    "fp": "FY",
    "form": "20-F",
    "filed": "2026-02-24",
    "frame": "CY2025",
    "tag": "ifrs-full:GrossProfit",
    "unit": "USD"
  },
  "operatingIncome": {
    "start": "2025-01-01",
    "end": "2025-12-31",
    "val": 13743000000,
    "accn": "0001104659-26-019130",
    "fy": 2025,
    "fp": "FY",
    "form": "20-F",
    "filed": "2026-02-24",
    "frame": "CY2025",
    "tag": "ifrs-full:ProfitLossFromOperatingActivities",
    "unit": "USD"
  },
  "eps": {
    "start": "2025-01-01",
    "end": "2025-12-31",
    "val": 6.54,
    "accn": "0001104659-26-019130",
    "fy": 2025,
    "fp": "FY",
    "form": "20-F",
    "filed": "2026-02-24",
    "frame": "CY2025",
    "tag": "ifrs-full:DilutedEarningsLossPerShare",
    "unit": "USD/shares"
  },
  "operatingCashFlow": {
    "start": "2025-01-01",
    "end": "2025-12-31",
    "val": 14575000000,
    "accn": "0001104659-26-019130",
    "fy": 2025,
    "fp": "FY",
    "form": "20-F",
    "filed": "2026-02-24",
    "frame": "CY2025",
    "tag": "ifrs-full:CashFlowsFromUsedInOperatingActivities",
    "unit": "USD"
  },
  "totalAssets": {
    "end": "2025-12-31",
    "val": 114074000000,
    "accn": "0001104659-26-019130",
    "fy": 2025,
    "fp": "FY",
    "form": "20-F",
    "filed": "2026-02-24",
    "frame": "CY2025Q4I",
    "tag": "ifrs-full:Assets",
    "unit": "USD"
  },
  "totalLiabilities": {
    "end": "2025-12-31",
    "val": 65355000000,
    "accn": "0001104659-26-019130",
    "fy": 2025,
    "fp": "FY",
    "form": "20-F",
    "filed": "2026-02-24",
    "frame": "CY2025Q4I",
    "tag": "ifrs-full:Liabilities",
    "unit": "USD"
  },
  "shareholdersEquity": {
    "end": "2025-12-31",
    "val": 48667000000,
    "accn": "0001104659-26-019130",
    "fy": 2025,
    "fp": "FY",
    "form": "20-F",
    "filed": "2026-02-24",
    "frame": "CY2025Q4I",
    "tag": "ifrs-full:EquityAttributableToOwnersOfParent",
    "unit": "USD"
  },
  "currentAssets": {
    "end": "2025-12-31",
    "val": 28723000000,
    "accn": "0001104659-26-019130",
    "fy": 2025,
    "fp": "FY",
    "form": "20-F",
    "filed": "2026-02-24",
    "frame": "CY2025Q4I",
    "tag": "ifrs-full:CurrentAssets",
    "unit": "USD"
  },
  "currentLiabilities": {
    "end": "2025-12-31",
    "val": 30617000000,
    "accn": "0001104659-26-019130",
    "fy": 2025,
    "fp": "FY",
    "form": "20-F",
    "filed": "2026-02-24",
    "frame": "CY2025Q4I",
    "tag": "ifrs-full:CurrentLiabilities",
    "unit": "USD"
  }
}

Annual earnings trend

Reported fiscal periods, not a live price chart.

Interactive chart loads in the browser. The full annual values are available below.

View all annual figures in a table
Period endRevenueNet incomeEPS
2025-12-31USD 58,739mUSD 10,233mUSD 6.54
2024-12-31USD 54,073mUSD 7,041mUSD 4.50
2023-12-31USD 45,811mUSD 5,961mUSD 3.81
2022-12-31USD 44,351mUSD 3,293mUSD 2.11

Valuation context

This release does not quote price-based multiples because it does not include synchronized market prices. A financial denominator must be paired with a clearly dated market value.

MeasureInterpretation
P/EPrice divided by EPS; identify annual, trailing or forward basis.
P/S & P/BMarket capitalization divided by sales or book equity.
EV / EBITDAEnterprise value and EBITDA need consistent definitions.
FCF yieldFree cash flow divided by dated market capitalization.

A sector median is descriptive, not a fair-value estimate. Explore sector context ↗

Selected filing notes

20-FFiled 2026-02-24Period 2025-12-31

AZN filed this 20-F on 2026-02-24 for the reported period 2025-12-31. Reading focus: Product concentration, research investment, utilization, reimbursement and cash generation. This is a metadata-based reading guide; it does not assert that a particular event or risk change occurred in the document.

Read SEC original ↗

Related research

Risks & what to monitor

Patent expiry, trial outcomes, reimbursement changes, litigation and acquisition integration.

Product concentration, research investment, utilization, reimbursement and cash generation.

Sources & dates